We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

78 hedge funds and large institutions have $513M invested in Amylyx Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

169% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 13

128% more call options, than puts

Call options by funds: $25.6M | Put options by funds: $11.3M

71% more capital invested

Capital invested by funds: $300M → $513M (+$213M)

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

8% more funds holding

Funds holding: 72 → 78 (+6)

4.01% more ownership

Funds ownership: 41.48% → 45.48% (+4%)

Holders
78
Holders Change
+6
Holders Change %
+8.33%
% of All Funds
1.31%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
20
Increased
35
Reduced
13
Closed
13
Calls
$25.6M
Puts
$11.3M
Net Calls
+$14.4M
Net Calls Change
+$9.15M

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$24.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$3.71M
3
Millennium Management
Millennium Management
New York
+$3.67M
4
Citadel Advisors
Citadel Advisors
Florida
+$3M
5
Belvedere Trading
Belvedere Trading
Illinois
+$2M

Top Sellers

Rank Fund Capital Flow
1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$9.59M
2
AII
AGF Investments Inc
Ontario, Canada
-$2.06M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.88M
4
IC
Ikarian Capital
Texas
-$1.78M
5
Wells Fargo
Wells Fargo
California
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
Group One Trading
26
Group One Trading
Illinois
$2.99M +$1.83M +154,145 +12,401%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$2.66M +$1.09M +91,664 +197%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$2.36M +$407K +34,318 +39%
Ameriprise
29
Ameriprise
Minnesota
$1.91M +$198K +16,645 +20%
Northern Trust
30
Northern Trust
Illinois
$1.82M +$147K +12,371 +15%
SEI Investments
31
SEI Investments
Pennsylvania
$1.81M +$1.11M +93,854 New
TLP
32
Tri Locum Partners
New York
$1.55M +$955K +80,459 New
AG
33
Artal Group
Luxembourg
$1.45M – – –
Charles Schwab
34
Charles Schwab
California
$1.36M -$31.1K -2,618 -4%
CM
35
Caption Management
Oklahoma
$1.34M +$392K +32,984 +90%
CSS
36
Cubist Systematic Strategies
Connecticut
$1.02M +$215K +18,086 +52%
Morgan Stanley
37
Morgan Stanley
New York
$829K +$9.04K +761 +2%
N
38
Nuveen
North Carolina
$761K +$312K +26,257 +198%
VF
39
Virtu Financial
New York
$693K +$427K +36,003 New
AllianceBernstein
40
AllianceBernstein
Tennessee
$691K +$426K +35,900 New
BFM
41
Boothbay Fund Management
New York
$664K -$163K -13,771 -29%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$558K +$30.5K +2,570 +10%
PMAM
43
Picton Mahoney Asset Management
Ontario, Canada
$446K +$275K +23,200 New
Bank of America
44
Bank of America
North Carolina
$319K +$162K +13,666 +471%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$312K +$192K +16,174 New
ECM
46
ExodusPoint Capital Management
New York
$308K +$190K +16,013 New
HT
47
HAP Trading
New York
$295K +$182K +15,322 New
PVI
48
Pura Vida Investments
New York
$203K +$6.53K +550 +6%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$177K +$61.7K +5,197 +130%
CG
50
Cutler Group
California
$148K +$91.5K +7,711 New
1
2
3 4

AMLX Hedge Fund Activity: Q2 2022 in Review

78 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2022, worth a combined $513M — up 71% from $300M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AMLX positions and 13 closed out — a net gain of 7 holders — while 35 added to existing stakes and 13 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $24.5M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $9.59M.

  • 78 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2022, up from 72 in Q1 2022.
  • Funds reported $513M of Amylyx Pharmaceuticals stock for Q2 2022, up 71% quarter-over-quarter.
  • 20 funds opened new Amylyx Pharmaceuticals positions in Q2 2022 and 13 closed out, a net change of +7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q2 2022 was Perceptive Advisors, an estimated $24.5M added.
  • The largest Amylyx Pharmaceuticals seller in Q2 2022 was Bain Capital Life Sciences Investors, an estimated $9.59M sold.

Based on aggregated 13F filings for Q2 2022.